创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

王华婷, 俞采妮, 康媛源, 李丹. 中药单体干预前列腺癌的作用机制研究进展[J]. 药学进展, 2022, 46(12): 951-960. DOI: 10.20053/j.issn1001-5094.2022.12.007
引用本文: 王华婷, 俞采妮, 康媛源, 李丹. 中药单体干预前列腺癌的作用机制研究进展[J]. 药学进展, 2022, 46(12): 951-960. DOI: 10.20053/j.issn1001-5094.2022.12.007
WANG Huating, YU Caini, KANG Yuanyuan, LI Dan. Progress of Research on the Mechanism of Action of Traditional Chinese Medicine Monomers in Prostate Cancer Intervention[J]. Progress in Pharmaceutical Sciences, 2022, 46(12): 951-960. DOI: 10.20053/j.issn1001-5094.2022.12.007
Citation: WANG Huating, YU Caini, KANG Yuanyuan, LI Dan. Progress of Research on the Mechanism of Action of Traditional Chinese Medicine Monomers in Prostate Cancer Intervention[J]. Progress in Pharmaceutical Sciences, 2022, 46(12): 951-960. DOI: 10.20053/j.issn1001-5094.2022.12.007

中药单体干预前列腺癌的作用机制研究进展

Progress of Research on the Mechanism of Action of Traditional Chinese Medicine Monomers in Prostate Cancer Intervention

  • 摘要: 前列腺癌是全球男性常见的恶性肿瘤,在我国也有较高的发病率和死亡率。中药单体结构明确且来源丰富,在开发前列腺癌治疗药物方面有着独特的优势。围绕雄激素受体依赖和雄激素受体非依赖两个方面综述了中药单体在前列腺癌治疗中的作用机制,以期为探索中药治疗前列腺癌的具体方案提供参考,为新型前列腺癌治疗药物的开发提供有用信息。

     

    Abstract: Prostate cancer (PCa), a common malignancy in men worldwide, has a high rate of morbidity and mortality in China. With their confirmed structures and rich sources, traditional Chinese medicine (TCM) monomers have their special advantages for developing anti-PCa drugs. This study reviews the action mechanisms of TCM monomers in the treatment of PCa from androgen receptor (AR) dependence and AR independence, so as to provide some reference for the exploration of specific PCa therapeutic regimens using TCM and useful information for the development of novel drugs treating PCa.

     

/

返回文章
返回